Read About Valbenazine Uses and General Medication Information

Valbenazine is an oral medication that belongs to the VMAT2 inhibitor class. It is approved for adults with tardive dyskinesia and for adults with chorea associated with Huntington disease. Tardive dyskinesia can involve repetitive, involuntary movements, while chorea is characterized by irregular, uncontrolled movements. The medication is intended to help manage these movement symptoms rather than cure the underlying conditions.

Valbenazine Uses and How the Medication Works

Valbenazine affects vesicular monoamine transporter 2, a protein involved in transporting certain neurotransmitters within nerve cells. By modifying this process, the medicine can influence signaling associated with abnormal movements. The FDA prescribing information identifies tardive dyskinesia and Huntington disease related chorea as its approved uses in adults.

Important general information includes:

• It is taken orally, with or without food.
• For tardive dyskinesia, the labeled starting dose is generally 40 mg once daily, with an increase to 80 mg once daily after one week when appropriate.
• For Huntington disease chorea, treatment generally starts at 40 mg once daily, with increases made gradually according to the prescribing information.
• Available capsule strengths include 40 mg, 60 mg, and 80 mg.
• Dosage adjustments may be necessary for certain liver conditions, genetic differences in drug metabolism, or interactions with other medicines.

The appropriate dose depends on the individual's medical circumstances and other medicines being taken. Valbenazine should therefore be used only as directed by a healthcare professional.

General Safety Information and Possible Side Effects

Like other prescription medicines, valbenazine can cause side effects and may require specific precautions. Somnolence, meaning sleepiness or sedation, is among the commonly reported adverse reactions. The prescribing information also describes potential risks involving heart rhythm, hypersensitivity reactions, parkinsonism, and neuroleptic malignant syndrome.

General safety considerations include:

• Sleepiness or sedation may affect activities such as driving or operating machinery.
• Valbenazine may prolong the QT interval, so certain people with heart rhythm conditions may require special consideration.
• Some medicines, including certain MAO inhibitors and strong CYP3A4 or CYP2D6 inhibitors, can affect how valbenazine is used.
• Patients should tell their healthcare professional about all prescription medicines, nonprescription medicines, and supplements they take.
• People with Huntington disease require particular attention to changes in mood or behavior because the FDA labeling includes a boxed warning concerning depression and suicidal thoughts or behavior.

Valbenazine is a medication that should be evaluated as part of an individual's overall treatment plan. The information above is intended for general education and does not replace professional medical advice. Anyone considering valbenazine or experiencing concerning symptoms while taking it should discuss them with a qualified healthcare professional.

Valbenazine is a VMAT2 inhibitor used in adults to manage tardive dyskinesia and chorea associated with Huntington disease. General medication information includes its approved uses, dosing considerations, potential side effects, interactions, and important safety precautions. Because individual circumstances can affect the appropriate dose and suitability of treatment, medical guidance is important when using this medication. This article provides informational content only and does not offer medical treatment, sales, or healthcare services.